Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dizal Pharmaceutical CoSHSE:688192 -3.86%27 PB Ratio is 19.32 as of Jul. 30, 2026, which is 4% above its 10-year median of 18.58. GuruFocus rates SHSE:688192 with a GF Score™ of 27/100 and a GF Value™ of ¥139.36 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 921 Drug Manufacturers companies, Dizal Pharmaceutical Co ranks worse than 97.18% on this metric.
The historical rank and industry rank for Dizal Pharmaceutical Co's PB Ratio or its related term are showing as below:
SHSE:688192'
s PB Ratio Range Over the Past 10 Years
Min: 3.66 Med: 18.58 Max: 1602.25
Current: 19.35
During the past 8 years, Dizal Pharmaceutical Co's highest PB Ratio was 1602.25. The lowest was 3.66. And the median was 18.58.
SHSE:688192's PB Ratio is ranked worse than 97.18% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs SHSE:688192: 19.35
During the past 12 months, Dizal Pharmaceutical Co's average Book Value Per Share Growth Rate was 6535.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -13.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -22.20% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Dizal Pharmaceutical Co was 59.20% per year. The lowest was -57.60% per year. And the median was -11.50% per year.
Back to Basics: PB Ratio
Dizal Pharmaceutical Co (SHSE:688192) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dizal Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dizal Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dizal Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Dizal Pharmaceutical Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Dizal Pharmaceutical Co (SHSE:688192) has a PB Ratio of 19.32 as of Jul. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Dizal Pharmaceutical Co and its competitors. This is near median its historical median of 18.58. Over the past decade, Dizal Pharmaceutical Co's PB Ratio has ranged from 3.66 to 1,602.25. According to the industry distribution chart, Dizal Pharmaceutical Co ranks #895 out of 921 companies in the Drug Manufacturers industry, placing it in the top 97.2%.
Is Dizal Pharmaceutical Co's PB Ratio too high?
Dizal Pharmaceutical Co's current PB Ratio of 19.32 is near median its 10-year median of 18.58. Over the past 10 years, this metric has ranged from a low of 3.66 to a high of 1,602.25. The Drug Manufacturers industry median PB Ratio is 1.90. Dizal Pharmaceutical Co's value of 19.32 is 916.8% above this industry median. Based on the distribution chart, Dizal Pharmaceutical Co ranks #895 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dizal Pharmaceutical Co has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dizal Pharmaceutical Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Dizal Pharmaceutical Co ranks #895 out of 921 companies for PB Ratio. This places Dizal Pharmaceutical Co in the lower half of its industry. The industry median PB Ratio is 1.90. Dizal Pharmaceutical Co's value of 19.32 is 916.8% above this benchmark. Historically, Dizal Pharmaceutical Co's own PB Ratio has ranged from 3.66 to 1,602.25 over the past decade. While the company's 10-year median is 18.58 vs. the industry median of 1.90, Dizal Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dizal Pharmaceutical Co's current PB Ratio of 19.32 is 916.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Dizal Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dizal Pharmaceutical Co's current PB Ratio is 19.32, which is near median its own 10-year median of 18.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dizal Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Dizal Pharmaceutical Co (SHSE:688192) is currently considered Possible Value Trap. The stock's GF Value™ is ¥139.36, compared to a current price of ¥51.27 — trading 63.2% below its estimated fair value. The current PB Ratio is 19.32, which is near median its 10-year median of 18.58 and 916.8% above the Drug Manufacturers industry median of 1.90. Dizal Pharmaceutical Co's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Dizal Pharmaceutical Co (SHSE:688192), the current PB Ratio is 19.32 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dizal Pharmaceutical Co (SHSE:688192) Overvalued in 2026?
Based on GuruFocus' analysis, Dizal Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥51.27 is trading 63.2% below its estimated GF Value™ of ¥139.36.
GuruFocus considers Dizal Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for SHSE:688192:
PB Ratio: 19.32 (near median its 10-year median of 18.58)
GF Value™: ¥139.36 vs. price of ¥51.27 (63.2% below fair value)
Industry Position: 916.8% above the Drug Manufacturers median (#895 of 921)
No single metric tells the full story. See the SHSE:688192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dizal Pharmaceutical Co Ltd, formerly Dizal (Jiangsu) Pharmaceutical Co Ltd is engaged in the research and development, production and sales of innovative drugs.
27GF Score
Get the complete analysis for SHSE:688192
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688192 has been successfully added to your 
